Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CSL ( (AU:CSL) ) just unveiled an announcement.
CSL Limited announced the cessation of 110,017 securities due to the lapse of conditional rights as the conditions were not met by September 1, 2025. This announcement may impact the company’s capital structure and could have implications for stakeholders, reflecting the company’s ongoing adjustments in its securities management.
The most recent analyst rating on (AU:CSL) stock is a Buy with a A$232.00 price target. To see the full list of analyst forecasts on CSL stock, see the AU:CSL Stock Forecast page.
More about CSL
CSL Limited is a global biotechnology company that operates in the pharmaceutical industry. It specializes in the development and manufacture of innovative medicines, with a focus on products for rare and serious diseases.
Average Trading Volume: 1,007,797
Technical Sentiment Signal: Sell
Current Market Cap: A$100.9B
For a thorough assessment of CSL stock, go to TipRanks’ Stock Analysis page.